Nutra Pharma Corp. (OTCQB: NPHC) is introducing new
healthcare solutions to the globe. Through ReceptoPharm, a subsidiary, Nutra
Pharma is discovering, researching and developing biopharmaceutical products to
prevent and/or treat multiple sclerosis (MS), HIV/AIDS, adrenomyeloneuropathy
(ADM), herpes, rheumatoid arthritis and pain.
Drug Discovery & Development
Nutra Pharma is in the business of acquiring, licensing and
commercializing pharmaceutical products and technologies, along with
homeopathic and ethical drugs for managing pain and neurological disorders,
autoimmune and infectious diseases and cancer.
The company has several pipeline products both in the market
and under research and development. Within the over-the-counter pain management
market, Nutra Pharma is already marketing:
Nyloxin and Nyloxin Extra Strength, homeopathic drugs used
to alleviate moderate to severe chronic pain; and
Pet Pain-Away, a homeopathic, non-addictive, non-narcotic
pain reliever aimed at treating moderate to severe chronic pain in companion
animals.
Nutra Pharma also has more than a few novel therapies in
various stages of development, including:
·
Nyloxin Military Strength, a pain relieving drug
intended for sale to the U.S. Military and Veteran's Administration;
·
RPI-MN, a drug designed to treat viral diseases,
such as HIV/AIDS and herpes;
·
RPI-78, which is geared toward managing pain and
arthritis;
·
RPI-70, another pain reliever;
·
Equine Nyloxin, a topical therapy for horses;
and
·
RPI-78M, which is designed to treat neurological
diseases and autoimmune diseases, including MS, ADM and rheumatoid arthritis.
·
Through RPI-78M, Nutra Pharma reached new heights this year.
In September, the U.S. Food and Drug Administration granted RPI-78M
"orphan drug status" for the treatment of multiple sclerosis in
children - a major milestone for the company. Not only is juvenile MS an
important disease area, but it is one that is not being addressed by other
drugs currently on the market. This creates a significant market opportunity
for Nutra Pharma, as does the designation of RPI-78M as an orphan drug. With
that label, Nutra Pharma has a 7-year period of market exclusivity in the U.S.
once the drug is approved, and, based on its pre-clinical and open-label
studies, the company feels quite strongly that it has the ability to
successfully pass through this approval process.
For more information on the company, visit
www.NutraPharma.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment